P7170

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 565099

CAS#: 1799702-72-9

Description: P7170 is an anti-cancer agent active as an mTORC1/C2 and activin receptor-like kinase 1 (ALK1) inhibitor.


Price and Availability

Size
Price

Size
Price

Size
Price

P7170 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 565099
Name: P7170
CAS#: 1799702-72-9
Chemical Formula: C21H16F3N9
Exact Mass: 451.1481
Molecular Weight: 451.42
Elemental Analysis: C, 55.88; H, 3.57; F, 12.63; N, 27.93


Synonym: P-7170; P7170; P 7170

IUPAC/Chemical Name: 8-Amino-1-[6-(cyano-dimethyl-methyl)-pyridin-3-yl]-3-methyl-7-trifluoromethyl-1,3-dihydro-1,3,5,9-tetraaza-cyclopenta[a]naphthalen-2-ylidene-cyanamide

InChi Key: VGAYQXQQPMBRDX-NDZAJKAJSA-N

InChi Code: InChI=1S/C21H16F3N9/c1-20(2,9-25)15-5-4-11(7-29-15)33-17-14(32(3)19(33)30-10-26)8-28-13-6-12(21(22,23)24)18(27)31-16(13)17/h4-8H,1-3H3,(H2,27,31)/b30-19+

SMILES Code: N#C/N=C(N1C2=CC=C(C(C)(C#N)C)N=C2)\N(C)C3=C1C4=NC(N)=C(C(F)(F)F)C=C4N=C3


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934990300


References

1: Jalota-Badhwar A, Bhatia DR, Boreddy S, Joshi A, Venkatraman M, Desai N, Chaudhari S, Bose J, Kolla LS, Deore V, Yewalkar N, Kumar S, Sharma R, Damre A, More A, Sharma S, Agarwal VR. P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity. Mol Cancer Ther. 2015 May;14(5):1095-106. doi: 10.1158/1535-7163.MCT-14-0486. Epub 2015 Feb 19. PubMed PMID: 25700704.

2: Bean JR, Hosford SR, Symonds LK, Owens P, Dillon LM, Yang W, Shee K, Schwartz GN, Marotti JD, Muller KE, Rosenkranz KM, Barth RJ, Chen VS, Agarwal VR, Miller TW. The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer. Breast Cancer Res Treat. 2015 Jan;149(1):69-79. doi: 10.1007/s10549-014-3201-6. Epub 2014 Dec 10. PubMed PMID: 25491778; PubMed Central PMCID: PMC4302040.

3: Venkatesha VA, Joshi A, Venkataraman M, Sonawane V, Bhatia D, Tannu P, Bose J, Choudhari S, Srivastava A, Pandey PK, Lad VJ, Sangana R, Ahmed T, Damre A, Deore V, Sahu B, Kumar S, Sharma S, Agarwal VR. P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer. Mol Cancer. 2014 Dec 2;13:259. doi: 10.1186/1476-4598-13-259. PubMed PMID: 25466244; PubMed Central PMCID: PMC4289333.